HUE059169T2 - Baktériumterápia Clostridium difficile colitis számára - Google Patents

Baktériumterápia Clostridium difficile colitis számára

Info

Publication number
HUE059169T2
HUE059169T2 HUE19176151A HUE19176151A HUE059169T2 HU E059169 T2 HUE059169 T2 HU E059169T2 HU E19176151 A HUE19176151 A HU E19176151A HU E19176151 A HUE19176151 A HU E19176151A HU E059169 T2 HUE059169 T2 HU E059169T2
Authority
HU
Hungary
Prior art keywords
bacteriotherapy
clostridium difficile
difficile colitis
colitis
clostridium
Prior art date
Application number
HUE19176151A
Other languages
English (en)
Inventor
Edwin J Hlavka
Original Assignee
Rebiotix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rebiotix Inc filed Critical Rebiotix Inc
Publication of HUE059169T2 publication Critical patent/HUE059169T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04Preserving or maintaining viable microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HUE19176151A 2010-02-01 2011-02-01 Baktériumterápia Clostridium difficile colitis számára HUE059169T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33728310P 2010-02-01 2010-02-01
US35118410P 2010-06-03 2010-06-03

Publications (1)

Publication Number Publication Date
HUE059169T2 true HUE059169T2 (hu) 2022-10-28

Family

ID=44319684

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19176151A HUE059169T2 (hu) 2010-02-01 2011-02-01 Baktériumterápia Clostridium difficile colitis számára

Country Status (14)

Country Link
US (8) US9629881B2 (hu)
EP (4) EP3181684B1 (hu)
AU (1) AU2011209940B2 (hu)
CA (1) CA2788558C (hu)
DK (1) DK3564357T3 (hu)
ES (3) ES2730828T3 (hu)
HR (1) HRP20220751T1 (hu)
HU (1) HUE059169T2 (hu)
LT (1) LT3564357T (hu)
PL (1) PL3564357T3 (hu)
PT (1) PT3564357T (hu)
RS (1) RS63299B1 (hu)
SI (1) SI3564357T1 (hu)
WO (1) WO2011094027A1 (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
RU2013109251A (ru) 2010-08-04 2014-09-10 Томас Джулиус БОРОДИ Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки
SG193348A1 (en) 2011-03-09 2013-10-30 Univ Minnesota Compositions and methods for transplantation of colon microbiota
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
EP2850202B1 (en) 2012-05-18 2020-03-11 Genome Research Limited Methods and groups
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2956006A4 (en) 2013-02-04 2017-02-22 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3375447A1 (en) 2013-06-05 2018-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2985729C (en) 2015-05-11 2023-05-09 Mybiotics Pharma Ltd Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
EP3297644B1 (en) 2015-05-22 2022-01-19 Arizona Board of Regents on behalf of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CA2986915C (en) 2015-06-09 2023-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
AU2017271491A1 (en) 2016-05-25 2018-12-13 Mybiotics Pharma Ltd. Composition and methods for microbiota therapy
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
KR102530297B1 (ko) 2016-09-27 2023-05-10 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
JP2020513018A (ja) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病(pd)および関連する障害を治療するための組成物および方法
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 健康な腸バリアを維持及び回復するための組成物及び方法
CA3072206A1 (en) 2017-08-14 2019-02-21 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2020536548A (ja) 2017-10-13 2020-12-17 レビオティクス インコーポレイテッドRebiotix,Inc. マイクロバイオーム健康指数
WO2019213595A1 (en) 2018-05-04 2019-11-07 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
CN112566649A (zh) 2018-06-14 2021-03-26 雷柏奥提斯有限公司 微生物群恢复治疗(mrt)组合物和制造方法
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN112888447A (zh) * 2018-08-17 2021-06-01 韦丹塔生物科学股份有限公司 减少菌群失调和恢复微生物群系的方法
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
US20220080001A1 (en) * 2019-01-16 2022-03-17 Board Of Regents, The University Of Texas System Methods and compositions for treating immune checkpoint inhibitor associated colitis
WO2021096794A1 (en) * 2019-11-11 2021-05-20 Hazan Sabine Method of treating an individual with a health condition with fecal microbiota transplant
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
KR20230018389A (ko) 2020-06-01 2023-02-07 훼링 비.브이. 질 미생물총 조성물
WO2022051610A1 (en) 2020-09-04 2022-03-10 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US12011467B2 (en) 2021-05-18 2024-06-18 J. Craig Venter Institute, Inc. Bacterial formulation
WO2023150544A1 (en) * 2022-02-01 2023-08-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Simplified method of preparing cells for patient administration

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL257275A (hu) 1959-10-26
US3261761A (en) 1962-05-07 1966-07-19 Arthur W Anderson Method of freeze drying bacterial cultures
WO1984004037A1 (en) 1983-04-13 1984-10-25 Field Group Res Pty Ltd Enema bag
WO1989003219A1 (en) 1987-10-12 1989-04-20 Borody Thomas J Improved method for treatment of gastrointestinal disorders
DE3744745A1 (de) 1987-12-04 1989-06-15 Claus Dr Med Jansen Elektroakustischer wandler
EP0397689B1 (en) 1987-12-24 1994-05-11 BORODY, Thomas Julius Orthostatic lavage solutions
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
CA1337265C (en) 1988-08-04 1995-10-10 Thomas Julius Borody Oral antibody therapy for patients with lowered immune response and composition therefor
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
ES2213139T5 (es) 1990-10-22 2011-03-18 Centre For Digestive Diseases Pty Ltd Tratamiento de trastornos intestinales no inflamatorios.
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5229374A (en) 1992-01-28 1993-07-20 Burton Albert F Method for treatment of lower gastrointestinal tract disorders
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5656283A (en) 1995-06-08 1997-08-12 Ortho Pharmaceutical Corporation In-situ lyophilization of vaginal suppository in unit dose applicator and resultant product
ATE310391T1 (de) 1995-09-15 2005-12-15 Dale N Gerding Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
US6103268A (en) 1995-11-03 2000-08-15 Borody; Thomas Julius Administering osmotic colonic evacuant containing a picosulfate
US5925354A (en) 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US5711446A (en) * 1996-01-16 1998-01-27 Sorenson Bioscience, Inc. Cryogenic freezing vial
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
CA2307331C (en) 1997-10-20 2017-03-21 Oravax, Inc. Passive immunization against clostridium difficile disease
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000016619A1 (en) 1998-09-21 2000-03-30 21St Century Medicine, Inc. Polyvinyl alcohol compounds for inhibition of ice growth
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7430478B2 (en) * 2000-03-01 2008-09-30 Caridian Bct, Inc. Blood processing information system with blood loss equivalency tracking
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
JP2001327280A (ja) 2000-05-23 2001-11-27 Lion Corp 菌用凍結保存液
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
EP1296693A4 (en) 2000-06-19 2005-05-25 Mucoprotec Pty Ltd IMMUNOTHERAPY AND PROBIOTIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL OR VIRAL INFECTIONS ON MUCOSAL SURFACES
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2427898C (en) 2000-11-14 2017-08-15 Techlab, Inc. Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker
CA2436574A1 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Laboratory scale milling process
MEP32608A (en) 2001-06-26 2011-02-10 Amgen Fremont Inc Antibodies to opgl
AU2002365913A1 (en) 2001-09-06 2003-09-16 Genomic Profiling Systems, Inc. Rapid and sensitive detection of cells and viruses
EP1300472A1 (en) 2001-10-02 2003-04-09 Stichting Top-Instituut Voedselwetenschappen A method for testing the effect of nutrients on gastrointestinal colonisation resistance of humans
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
EP1448987A4 (en) * 2001-12-10 2005-06-08 Ardais Corp SYSTEM AND METHODS FOR OBTAINING PATIENT SAMPLES IN CORRELATION WITH DATA
US20030161871A1 (en) 2001-12-19 2003-08-28 Geoffrey Hird Solubilized riboflavin
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
AU2003225973A1 (en) 2002-03-26 2003-11-11 Glaxo Group Limited A method for forming a laminate assembly and products formed thereby
EP1596872B1 (en) 2003-01-24 2011-06-22 Flora Technology Inc. Compositions and methods for restoring bacterial flora
GB0322791D0 (en) 2003-09-30 2003-10-29 Lifeforce Group Plc Blood co-processing for contingent autologous leukocyte transplantation
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US7935334B2 (en) 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
US20060008511A1 (en) 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
US7909806B2 (en) 2004-09-23 2011-03-22 Anthrogenesis Corporation Cord blood and placenta collection kit
EP1817432A2 (en) 2004-10-05 2007-08-15 Wyeth a Corporation of the State of Delaware Probe arrays for detecting multiple strains of different species
CA2586998A1 (en) 2004-11-08 2006-05-26 Yale University Structure-based compound design involving riboswitches
US20080075901A1 (en) 2005-02-23 2008-03-27 Lee S Thomas Multilayer Films Including Cycloolefin Copolymer and Styrene-Butadiene Copolymer
US20060210448A1 (en) 2005-03-10 2006-09-21 Naishu Wang Fecal specimen collection, preserving and transport device and method
EP2783688A1 (en) 2005-03-17 2014-10-01 Synhton B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
US7607776B1 (en) 2005-10-24 2009-10-27 James Waller Lambuth Lewis Digital eye bank for virtual clinic trials
JP2009524411A (ja) 2005-12-21 2009-07-02 イェール ユニバーシティー リボスイッチの調節に関連した方法および組成物
BRPI0620734A2 (pt) 2005-12-29 2012-09-18 Hill's Pet Nutrition, Inc método para melhorar o equilìbrio de bactérias benéficas e nocivas no trato gastrintestinal de um animal, uso de pelo menos um antioxidante, composição de ração, kit, e meio para comunicação de informação e/ou instruções
US20080008751A1 (en) 2006-07-10 2008-01-10 Michael Fox Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
US20080027353A1 (en) 2006-07-31 2008-01-31 Kliman Harvey J Method of making and using a library of biological information
CN101605566A (zh) 2006-10-13 2009-12-16 利莱恩斯生命科学有限公司 生物聚合物上的培养黑素细胞
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
WO2009029315A2 (en) 2007-05-31 2009-03-05 University Of Washington Inducible mutagenesis of target genes
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2009042645A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College The use of mice predisposed to develop ulcerative colitis and colon cancer to develop metabolic profiles associated with same
CA2740434C (en) 2007-10-26 2017-11-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
US20090138354A1 (en) 2007-11-25 2009-05-28 Herbert Zech Methods of Storing and Providing Samples of Cells and Tissue
US20090148540A1 (en) 2007-12-10 2009-06-11 Mi Hope Incorporated Antibacterial composition and method of production
US8338812B2 (en) 2008-01-16 2012-12-25 Micron Technology, Inc. Vertical spacer electrodes for variable-resistance material memories and vertical spacer variable-resistance material memory cells
WO2009120347A2 (en) 2008-03-27 2009-10-01 Memorial Sloan Kettering Cancer Center Modulators of rna riboswitches
EP2310532B1 (en) 2008-06-30 2014-05-07 The Washington University Methods of promoting weight loss and associated arrays
US20100008850A1 (en) 2008-07-14 2010-01-14 William John Martin Method of generating hydrogen in drinking water using an enerceutical product added to magnesium in a hydrogen permeable but solute impermeable container
CN104247718A (zh) 2008-07-17 2014-12-31 生物工厂公司 利用绿木霉物种与根际活性的哈茨木霉物种的组合来控制植物疾病与增强植物生长
CN102176825A (zh) 2008-08-11 2011-09-07 佰欧莱利克斯公司 黄素衍生物
TW201022253A (en) 2008-11-14 2010-06-16 Portola Pharm Inc Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
US20110240511A1 (en) 2008-12-10 2011-10-06 Merck Sharp & Dohme Corp. Packaging for oxygen-sensitive pharmaceutical products
BRPI1010874A8 (pt) 2009-05-01 2018-01-02 Ferring Bv composição para o tratamento de câncer de próstata
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20120177650A1 (en) 2009-09-23 2012-07-12 Borody Thomas J Therapy for enteric infections
GB2548296A (en) 2009-10-22 2017-09-13 Borody Thomas J Novel parasite therapy
JP2013508428A (ja) 2009-10-26 2013-03-07 トーマス・ジュリアス・ボロディ 新規な腸の併用療法
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
US20130005586A1 (en) 2010-03-01 2013-01-03 Stanislav Ehrlich Method of diagnostic of obesity
EP2542690A2 (en) 2010-03-01 2013-01-09 Institut National de la Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
FI20105825A (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
WO2012013861A2 (en) 2010-07-26 2012-02-02 Suomen Punainen Risti Veripalvelu Use of blood group status iii
RU2013109251A (ru) 2010-08-04 2014-09-10 Томас Джулиус БОРОДИ Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012033814A2 (en) 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
WO2012050513A1 (en) 2010-10-11 2012-04-19 Baeckhed Fredrik Method for identifying a risk of cardiovascular disease by analysing oral microbiota
EP2680866A1 (en) 2011-03-01 2014-01-08 Quorum Innovations, LLC Materials and methods for treating conditions associated with pathogenic biofilm
WO2014152484A1 (en) 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
SG193348A1 (en) 2011-03-09 2013-10-30 Univ Minnesota Compositions and methods for transplantation of colon microbiota
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120276059A1 (en) 2011-04-29 2012-11-01 Techlab, Inc. Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
JP2014525266A (ja) 2011-08-26 2014-09-29 マイクロバイオータ ダイアグノスティクス, エルエルシー 心欠陥を診断および治療する方法
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
WO2013053836A1 (en) 2011-10-11 2013-04-18 Quantum Pharmaceuticals Sa Composition comprising anaerobically cultivated human intestinal microbiota
US20140360404A1 (en) 2011-11-09 2014-12-11 Capsugel Belgium Nv Acid resistant banding solution for acid resistant two piece hard capsules
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
CN108771687A (zh) 2012-02-29 2018-11-09 伊西康内外科公司 微生物区系的组合物及与其相关的方法
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
WO2013163582A1 (en) 2012-04-27 2013-10-31 Cedars-Sinai Medical Center Fungal mycobiome as probiotics, diagnostics and therapeutics
EP2850202B1 (en) 2012-05-18 2020-03-11 Genome Research Limited Methods and groups
JP2015522003A (ja) 2012-07-02 2015-08-03 ディーエスエム アイピー アセッツ ビー.ブイ. チモキノンを含有するカプセル
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2896795A1 (en) 2012-11-26 2014-05-30 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
WO2014082132A1 (en) 2012-11-29 2014-06-05 Progel Pty Ltd Microparticles comprising a probiotic, cross-linkable reagent, a denatured protein, polyol plasticiser and trehalose
CA2896192C (en) 2012-12-23 2021-01-12 Illuminate Consulting, Llc. Method and apparatus for thermally protecting and/or transporting temperature sensitive products
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2956006A4 (en) 2013-02-04 2017-02-22 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US9192361B2 (en) 2013-02-26 2015-11-24 Christopher J Stevens Fecal microbiome transplant material preparation method and apparatus
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3375447A1 (en) 2013-06-05 2018-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US20150037285A1 (en) 2013-07-03 2015-02-05 New York University Methods for efficient transfer of viable and bioactive microbiota
US20160206668A1 (en) 2013-08-22 2016-07-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Production of probiotics by in vitro enrichment of beneficial microorganisms from human or animal microbiota
JP2015091647A (ja) 2013-09-30 2015-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 マーキング方法、レーザー転写フィルム、インク組成物、マークが施された転写対象可食物及びその製造方法
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
EP3297644B1 (en) 2015-05-22 2022-01-19 Arizona Board of Regents on behalf of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
EP3303401B1 (en) 2015-06-01 2024-10-16 The University of Chicago Treatment of cancer by manipulation of commensal microflora
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CA2986915C (en) 2015-06-09 2023-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10173160B2 (en) 2015-10-09 2019-01-08 Heinzen, Llc Effluent removal system and method of use
ITUB20169847A1 (it) 2016-01-05 2017-07-05 Wellmicro S R L Metodo per valutare lo stato di salute di un individuo
US20180000872A1 (en) 2016-07-01 2018-01-04 Regents Of The University Of Minnesota Compositions and methods for c. difficile treatment
EP3823652A1 (en) 2018-07-17 2021-05-26 Ferring BV Combination therapy comprising microbiota restoration therapy (mrt) compositions

Also Published As

Publication number Publication date
PT3564357T (pt) 2022-06-14
US11944654B2 (en) 2024-04-02
ES2916399T3 (es) 2022-06-30
AU2011209940A1 (en) 2012-08-23
CA2788558A1 (en) 2011-08-04
US20170266241A1 (en) 2017-09-21
US20130045274A1 (en) 2013-02-21
CA2788558C (en) 2015-11-24
US20180243351A1 (en) 2018-08-30
LT3564357T (lt) 2022-07-11
RS63299B1 (sr) 2022-07-29
EP3181684B1 (en) 2019-05-29
SI3564357T1 (sl) 2022-09-30
AU2011209940B2 (en) 2015-08-20
AU2011209940A2 (en) 2012-08-30
US20240122995A1 (en) 2024-04-18
US20160367607A1 (en) 2016-12-22
ES2730828T3 (es) 2019-11-12
WO2011094027A1 (en) 2011-08-04
ES2623127T3 (es) 2017-07-10
EP3564357A1 (en) 2019-11-06
EP2531589B1 (en) 2017-04-05
DK3564357T3 (da) 2022-06-20
EP2531589A1 (en) 2012-12-12
EP4032586A1 (en) 2022-07-27
US20140086877A1 (en) 2014-03-27
EP3181684A1 (en) 2017-06-21
PL3564357T3 (pl) 2022-08-08
US12102655B2 (en) 2024-10-01
US9629881B2 (en) 2017-04-25
EP3564357B1 (en) 2022-04-06
US11446337B2 (en) 2022-09-20
US11986500B2 (en) 2024-05-21
HRP20220751T1 (hr) 2022-09-02
US9463208B2 (en) 2016-10-11
US20230076826A1 (en) 2023-03-09
US20240252556A1 (en) 2024-08-01
EP2531589A4 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
SI3564357T1 (sl) Bakterioterapija Clostridium Difficile colitisa
GB2498008B (en) State transition
DK3327110T3 (en) Kassette til sterilitetstest
GB2506331B (en) Seal member
DK2737264T3 (en) Startlogik til kølesystem
GB201016742D0 (en) Clostridium difficile antigens
HK1199886A1 (en) Clostridium difficile antibodies
HK1189301A1 (zh) 開關裝置
ZA201409097B (en) Solid state bioreactor adapted for automation
GB2495092B (en) Sealing arrangement
HK1202805A1 (en) Clostridium difficile antigens
IL232957A0 (en) A composition based on clostridium difficile toxin
HK1216999A1 (zh) 針對艱難梭菌的抗體
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
EP2548959A4 (en) FLORIGENIC ACTIVATOR COMPLEX
GB201105625D0 (en) Seal
ZA201403228B (en) Heterocyclypyri(mi)dinylpyrazole
EP2765177A4 (en) GASIFICATION SYSTEM
GB201120213D0 (en) B0-U component seal
GB201107459D0 (en) Seal
ZA201402298B (en) Heterocyclylpyri (mi)dinylpyrazole as fungicidals
EP2780351A4 (en) LIPOTHEICHOIC ACID OF DIFFICULT CLOSTRIDIUM AND USES THEREOF
GB2500854B (en) Biosurface engineering
PL2495467T3 (pl) System uszczelniający
GB201010960D0 (en) Complex